Clinical Trial Update: Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase II neoadjuvant trial combining pembrolizumab with carboplatin and docetaxel in triple-negative breast cancer is ongoing with active not recruiting statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-04-11